FDA Panel Calls For More Studies Of Mini-Slings For Urinary Incontinence
This article was originally published in The Gray Sheet
FDA’s Obstetrics and Gynecology Device panel recommends second-generation mini-slings to treat stress urinary incontinence be subject to 510(k) pre-market clinical trial requirements and additional post-market data collection mandates.
You may also be interested in...
FDA sends post-market study orders to 33 manufacturers of urogynecologic surgical mesh used for pelvic organ prolapse and to seven makers of single-incision mini-slings used for stress urinary incontinence.
Current and future surgical mesh devices for pelvic organ prolapse repair would require PMA submissions under a recommendation last week by FDA’s Obstetrics and Gynecology Devices panel.
Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue
At advisory committee meeting on Acrotech's two peripheral T-cell lymphoma drugs, FDA reviewers suggest they are more willing to seek product withdrawal for failure to conduct studies with due diligence when there are numerous available therapies.